63301-13-3

Upstream product

• 51-78-5 p-aminophenol hydrochloride 
• 98-60-2 4-chlorobenzenesulfonyl chloride 
• 123-30-8 4-amino-phenol 

Downstream Products

• 881943-05-1 N-(3-((1H-1,2,4-triazol-5-yl)thio)-4-hydroxyphenyl)-4-chlorobenzenesulfonamide 
• 141481-34-7 N-p-chlorobenzenesulfonyl-2,3,6-trichloro-1,4-benzoquinone imine 
• 146463-23-2 4-Chloro-N-(3,5-dibromo-4-hydroxy-phenyl)-benzenesulfonamide 
• 146463-12-9 N-(3-Bromo-4-hydroxy-phenyl)-4-chloro-benzenesulfonamide 
• 141481-38-1 4-Chloro-N-[2,3,5,5,6,6-hexachloro-4-oxo-cyclohex-2-en-(Z)-ylidene]-benzenesulfonamide 
• 141494-10-2 N-p-chlorobenzenesulfonyl-2,3,5,6-tetrachloro-1,4-benzoquinone imine 
• 141481-33-6 N-p-chlorophenylsulfonyl-2,3,6-trichloro-4-aminophenol 
• 118-75-2 chloranil 
• 38250-73-6 4-chloro-N-(4-oxocyclohexa-2,5-dien-1-ylidene)benzenesulfonamide 
• 14504-09-7 2,3,5,5,6,6-hexachloro-2-cyclohexene-1,4-dione 
• 488-48-2 tetrabromobenzoquinone 

Relevant academic research and scientific papers

Synthesis of indole-fused scaffolds via [3+3] cyclization reaction of 2-indolylmethanols with quinone imines

A formal [3 + 3] cyclization reaction of 2-indolylmethanols with quinones was realized to furnish indole-fused scaffolds in moderate to excellent yields. This protocol was proceeded smoothly under acid condition, with high high yields and broad substrate scope.

Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part II

A novel series of 4-amino-2-(thio)phenol derivatives were well synthesized. The preliminary biological test revealed that several compounds displayed high specific protein kinase and angiogenesis inhibitory activities compared with previous work mainly because of the substitution of sulfonamide structure for amide fragment. Among which, compound 5i was identified to inhibit protein kinase B/AKT (IC50 = 1.26 μM) and ABL tyrosine kinase (IC 50 = 1.50 μM) effectively. Meanwhile, compound 5i demonstrated competitive in vitro antiangiogenic activities to Pazopanib in both human umbilical vein endothelial cell (HUVEC) tube formation assay and the rat thoracic aorta rings test.